Jeff Yass’s CG Oncology CGON Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$11.6M Buy
162,700
+132,500
+439% +$8.66M ﹤0.01% 3161
2026
Q1
$2.04M Buy
+30,200
New +$1.71M ﹤0.01% 6133
2025
Q4
Sell
-9,000
Closed -$363K 12456
2025
Q3
$363K Sell
9,000
-151,800
-94% -$4.41M ﹤0.01% 9687
2025
Q2
$4.18M Buy
+160,800
New +$3.87M ﹤0.01% 4314
2024
Q4
Sell
-30,300
Closed -$1.14M 12277
2024
Q3
$1.14M Buy
30,300
+23,900
+373% +$838K ﹤0.01% 6478
2024
Q2
$202K Buy
+6,400
New +$222K ﹤0.01% 10340

Other funds holding CGON

Jeff Yass's CGON Position: Q2 2026 in Review

Jeff Yass reduced its CG Oncology (CGON) stake by 39% in Q2 2026, selling an estimated $663K and leaving 15,653 shares worth $1.11M. The position accounts for ﹤0.01% of the portfolio, ranked #7927.

Jeff Yass first reported a position in CGON in Q1 2024 and has held it in 7 quarters since. The position peaked at $2.44M in Q2 2025. 227 funds tracked by Wall St. Rank hold CGON as of Q2 2026.

  • Jeff Yass held 15,653 shares of CG Oncology worth $1.11M as of Q2 2026.
  • Jeff Yass sold 10,150 CG Oncology shares in Q2 2026, an estimated $663K.
  • CG Oncology made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #7927 holding.
  • Jeff Yass first reported a position in CG Oncology in Q1 2024 and has held it in 7 quarters since.
  • Jeff Yass's CG Oncology position peaked at $2.44M in Q2 2025.
  • 227 funds tracked by Wall St. Rank held CG Oncology as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.